Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 218

1.

Recovery of drug-resistant influenza virus from immunocompromised patients: a case series.

Ison MG, Gubareva LV, Atmar RL, Treanor J, Hayden FG.

J Infect Dis. 2006 Mar 15;193(6):760-4. Epub 2006 Feb 13. Review.

PMID:
16479508
2.

Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors.

Gubareva LV.

Virus Res. 2004 Jul;103(1-2):199-203.

PMID:
15163510
3.

Phenotypic drug susceptibility assay for influenza virus neuraminidase inhibitors.

McSharry JJ, McDonough AC, Olson BA, Drusano GL.

Clin Diagn Lab Immunol. 2004 Jan;11(1):21-8.

4.

Molecular basis for the resistance of influenza viruses to 4-guanidino-Neu5Ac2en.

Staschke KA, Colacino JM, Baxter AJ, Air GM, Bansal A, Hornback WJ, Munroe JE, Laver WG.

Virology. 1995 Dec 20;214(2):642-6.

5.

Mutations of neuraminidase implicated in neuraminidase inhibitors resistance.

Ferraris O, Lina B.

J Clin Virol. 2008 Jan;41(1):13-9. Epub 2007 Dec 11. Review.

PMID:
18055254
6.

The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo.

Ives JA, Carr JA, Mendel DB, Tai CY, Lambkin R, Kelly L, Oxford JS, Hayden FG, Roberts NA.

Antiviral Res. 2002 Aug;55(2):307-17.

PMID:
12103431
7.

Virological surveillance and antiviral resistance of human influenza virus in Argentina, 2005-2008.

Pontoriero A, Baumeister E, Campos AM, Savy VL.

Rev Panam Salud Publica. 2011 Dec;30(6):634-40.

8.

Influenza virus susceptibility and resistance to oseltamivir.

Aoki FY, Boivin G, Roberts N.

Antivir Ther. 2007;12(4 Pt B):603-16. Review.

PMID:
17944268
9.
10.

A single E105K mutation far from the active site of influenza B virus neuraminidase contributes to reduced susceptibility to multiple neuraminidase-inhibitor drugs.

Fujisaki S, Takashita E, Yokoyama M, Taniwaki T, Xu H, Kishida N, Sato H, Tashiro M, Imai M, Odagiri T.

Biochem Biophys Res Commun. 2012 Dec 7;429(1-2):51-6. doi: 10.1016/j.bbrc.2012.10.095. Epub 2012 Nov 3.

PMID:
23131559
11.

[Role of neuraminidase inhibitors for the treatment of influenza A virus infections].

Ferraris O, Escuret V, Bouscambert-Duchamp M, Lina B, Morfin F.

Pathol Biol (Paris). 2010 Apr;58(2):e69-78. doi: 10.1016/j.patbio.2010.01.011. Epub 2010 Mar 19. Review. French.

PMID:
20303677
12.

Mutations conferring zanamivir resistance in human influenza virus N2 neuraminidases compromise virus fitness and are not stably maintained in vitro.

Z├╝rcher T, Yates PJ, Daly J, Sahasrabudhe A, Walters M, Dash L, Tisdale M, McKimm-Breschkin JL.

J Antimicrob Chemother. 2006 Oct;58(4):723-32. Epub 2006 Aug 5.

PMID:
16891631
13.

Shift in oligosaccharide specificities of hemagglutinin and neuraminidase of influenza B viruses resistant to neuraminidase inhibitors.

Mochalova L, Bright R, Xu X, Korchagina E, Chinarev A, Bovin N, Klimov A.

Glycoconj J. 2010 Apr;27(3):321-7. doi: 10.1007/s10719-010-9280-7. Epub 2010 Mar 2.

PMID:
20195900
14.

Detection of antiviral resistance and genetic lineage markers in influenza B virus neuraminidase using pyrosequencing.

Sheu TG, Deyde VM, Garten RJ, Klimov AI, Gubareva LV.

Antiviral Res. 2010 Feb;85(2):354-60. doi: 10.1016/j.antiviral.2009.10.022. Epub 2009 Nov 1.

PMID:
19887086
15.

[The molecular basis of resistance to anti-influenza drugs].

Hatakeyama S, Kawaoka Y.

Nihon Rinsho. 2006 Oct;64(10):1845-52. Review. Japanese.

PMID:
17037359
16.

Selection of influenza A and B viruses for resistance to 4-guanidino-Neu5Ac2en in cell culture.

Colacino JM, Laver WG, Air GM.

J Infect Dis. 1997 Aug;176 Suppl 1:S66-8.

PMID:
9240698
17.

Neuraminidase inhibitor susceptibility testing of influenza type B viruses in China during 2010 and 2011 identifies viruses with reduced susceptibility to oseltamivir and zanamivir.

Wang D, Sleeman K, Huang W, Nguyen HT, Levine M, Cheng Y, Li X, Tan M, Xing X, Xu X, Klimov AI, Gubareva LV, Shu Y.

Antiviral Res. 2013 Mar;97(3):240-4. doi: 10.1016/j.antiviral.2012.12.013. Epub 2012 Dec 23.

PMID:
23267831
18.

John F. Enders lecture 2006: antivirals for influenza.

Ong AK, Hayden FG.

J Infect Dis. 2007 Jul 15;196(2):181-90. Epub 2007 Jun 7.

PMID:
17570104
19.

In vitro selection and characterization of influenza A (A/N9) virus variants resistant to a novel neuraminidase inhibitor, A-315675.

Molla A, Kati W, Carrick R, Steffy K, Shi Y, Montgomery D, Gusick N, Stoll VS, Stewart KD, Ng TI, Maring C, Kempf DJ, Kohlbrenner W.

J Virol. 2002 Jun;76(11):5380-6.

20.

Characterization of 2 influenza A(H3N2) clinical isolates with reduced susceptibility to neuraminidase inhibitors due to mutations in the hemagglutinin gene.

Abed Y, Bourgault AM, Fenton RJ, Morley PJ, Gower D, Owens IJ, Tisdale M, Boivin G.

J Infect Dis. 2002 Oct 15;186(8):1074-80. Epub 2002 Sep 30.

PMID:
12355356

Supplemental Content

Support Center